1. Highly hypofractionated intensity-modulated radiation therapy for nonmetastatic prostate cancer with a simultaneous integrated boost to intraprostatic lesions: a planning study
- Author
-
Takashi Mizowaki, Ryo Ashida, Mitsuhiro Nakamura, Rihito Aizawa, Hiraku Iramina, Kenji Takayama, and Kiyonao Nakamura
- Subjects
Simultaneous integrated boost ,Male ,Organs at Risk ,medicine.medical_specialty ,medicine.medical_treatment ,Prostate cancer ,Prostate ,Planning study ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,medicine.diagnostic_test ,IPLs ,Dose escalation ,business.industry ,Radiotherapy Planning, Computer-Assisted ,SIB-IMRT ,Cancer ,Prostatic Neoplasms ,Magnetic resonance imaging ,Radiotherapy Dosage ,medicine.disease ,Radiation therapy ,medicine.anatomical_structure ,Hypofractionation ,Radiology ,Radiotherapy, Intensity-Modulated ,business ,Quality assurance - Abstract
PURPOSE: The purpose of this planning study was to develop an acceptable technique for highly hypofractionated intensity-modulated radiation therapy using simultaneous integrated boost technique (SIB-hHF-RT) for nonmetastatic National Comprehensive Cancer Network high-risk prostate cancer. MATERIALS AND METHODS: We created SIB-hHF-RT plans for 14 nonmetastatic prostate cancer patients with MRI-detectable intraprostatic lesions (IPLs) and without intestines locating close to the seminal vesicle and prostate. We prescribed 57Gy for IPLs and 54Gy for the remainder of planning target volume (PTV) in 15 fractions. The IPLs were contoured based on magnetic resonance imaging, and PTV was generated by adding 6-8-mm margins to the clinical target volume. For the dose-volume constraints of organs at risk (OARs), the same constraints as 54Gy plans were used so as not to increase the toxicity. RESULTS: All created plans fulfilled the dose-volume constraints of all targets and OARs. The median estimated beam-on time was 108.5s. For patient-specific quality assurance, the global gamma passing rates (3%/2mm) with 10% dose threshold criteria were greater than 93% in all cases and greater than 95% in 11 cases. CONCLUSION: SIB-hHF-RT plans were developed that fulfill the acceptable dose-volume constraints and pass patient-specific quality assurance. We believe these plans can be applied to selected patients with nonmetastatic prostate cancer.
- Published
- 2022